Sleep Apnea Implants Market Worth $803.26 Million by 2030 - Exclusive Report by The Insight Partners
18 oct. 2023 08h18 HE
|
The Insight Partners
Pune, India, Oct. 18, 2023 (GLOBE NEWSWIRE) -- North America accounted for the largest share of the global sleep apnea implants market in 2022. The North America sleep apnea implants market has...
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
18 oct. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
10 oct. 2023 08h30 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
02 oct. 2023 08h00 HE
|
Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
21 sept. 2023 08h30 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 sept. 2023 05h30 HE
|
Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
06 sept. 2023 08h00 HE
|
Apnimed, Inc.
-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month -- Exploratory Trial on the Impact of...
APNIMED to Participate in Upcoming Investor Conferences in September
30 août 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
28 août 2023 06h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Sleep Tech Devices Market revenue to reach USD 50 Billion by 2035, says Research Nester
10 août 2023 07h00 HE
|
Research Nester
New York, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The global sleep tech devices market size is slated to expand at ~15% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 50...